BLUSF-DD ..A FANTASTIC INVESTMENT TO MAKE BIG MONEY !!!
Just look at Volume and you will know that almost nobody knows this Monster Sleeping Giant with brutally upside potential means you have the opportunity to buy at the Bottom and before it hit the radar of investors .
Here is Why i like the Company so much :
1) Trading at Cash Level
2) Very Low Burn-Rate of $900k per Q (Cash untill Late 2017)
3) Strong Insider and Institutional Ownership (Holding 70% of the 47.3 M Share Outstanding )
4) KIACTA™ for AA Amyloidosis has Orphan Drug Status (NO approved Drugs for this Indication)
5) Previous Phase 3 of KIACTA™ was Successful and they just need the same results in the ongoing Phase 3 to get Approval
6) Great CEO who sold another Company for $4 B to Shire
Bellus Health (BLU.TO) (BLUSF)
Market Cap: $17.6 M
Cash: $16.3 M
Shares Outstanding: 47.4 M ( 70% of these Shares held by Insiders and Institutions)
New Slide Presentation ( Jan 2014) http://www.bellushealth.com/files/doc_presentations/Bellus%20Corporate%20Presentation%20January%202014%20vFINAL.pdf
Interview with Ceo (November 2013) http://watch.bnn.ca/#clip1047918
BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.
The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).
In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.
Some key reasons to consider investing in BELLUS Health include:
Focus on rare diseases – pipeline of rare disease projects in areas of high unmet medical need
Late stage pipeline – global Phase III study for KIACTA™ currently enrolling patients
Fully funded business plan – strong balance sheet with cash runway that will meet funding requirements beyond 2017
Key shareholders –shareholder base with proven track record of building successful healthcare companies
KIACTA™ peak annual revenues projected at $500 million (Summary)
Strong Clinical Results in First Phase III Study
Landmark study in AA amyloidosis: 183 patients treated for 2 years
Important benefits for patients on drug:
Statistically significant reduction in number and risk of reaching
worsening kidney event
Important delay in reaching dialysis New England Journal of
Medicine publication concludes that KIACTA TM slows decline of renal function in AA amyloidosis
Orphan drug designation granted with market protection in the U.S. (7years), Europe and Japan (10 years)
Formulation (Dosing Schedule) and Methods for Treating Amyloidosis with expiry in 2026 5 year patent extension can be applied to provide protection until 2031
KIACTA™ peak annual revenues projected at $500 million Clear pharmacoeconomic
rationale due to high cost of kidney disease Premium pricing for comparative rare disease drugs
Partnership to fund Phase III Confirmatory Study with significant upside for BELLUS shareholders
With global fund Auven Therapeutics, a private equity group specialized in drug development project
financing Auven Therapeutics funding 100% of KIACTA™’s Phase III Confirmatory Study
US$10M in upfront by Auven Therapeutics
US$50M in investments by Auven Therapeutics
Proceeds of exit expected to be shared 50-50